PubMed Health⌕ Search

Biomedical subjects

A M Garin

Publications and source records attributed to A M Garin.

At least 37 records · Page 2Linked to original sources
PubMed1991

VAB-6 and cisplatin-cyclophosphamide combinations in the treatment of metastatic seminoma patients: the U.S.S.R. experience.

In a non-randomized study the treatment results of 59 patients with disseminated seminoma were evaluated: 21 patients were treated with a VAB-6 combination and 38 with a CP (cyclophosphamide and cisplatin) combination. After VAB-6 CR was observed in 8 patients and 6 achieved CR with additional treatment: 1 with chemotherapy (PVB) and 5 with radiotherapy (RT). The final CR rate was 67%. At a median follow-up of 38 (11-70) months 15 (71%) are alive, and 11 of them (52%) are NED; 6 have died. Of the 38 patients treated with CP alone only 18 achieved CR and 9 had a CR after additional RT and 1 chemotherapy (VAB-6), the overall CR rate was 72%. The median follow-up is 24 (4-55) months, 28 (74%) are alive, 24 (66%) are currently NED, and 9 have died. Both regimens were well tolerated, the main toxicity being leukopenia: 48% (WHO grade 111-1V-5%) for VAB-6, and 59% (13%) for CP. Hearing loss was registered in 8 patients receiving CP and in 2 receiving VAB-6. There were no fatal toxicities. Thus, VAB-6 and CP regimens seem to have compatible and high activity in disseminated seminoma.

Adolescent↗
PubMed1989

[Biochemical tests in the diagnosis of nephrotoxicity: assessment of the significance].

In order to identify early signs of nephrotoxicity in 38 patients with malignant tumors of the testicle, the data of 3 biochemical tests (measurements of gamma-glutamyltranspeptidase (gamma-GT) activity in the urine, of the content of creatinine and urea in blood serum) were compared. Activation of gamma-GT in the urine may be viewed as the first and early sign of nephrotoxicity, since the rise of creatinine and urea in the blood was observed later. The magnitude of gamma-GT activity (means + 2 sigma) - 5.9 Units/mmo le Cr may provide basis for the judgement about nephrotoxicity according to the scheme applied. The fall of gamma-GT activity without any further increase after multiple courses of chemotherapy is of prognostic significance for its evidences profound injury to the renal parenchyma and may serve as basis for correcting the doses of chemotherapeutic drugs. The reduction of gamma-GT activity to less than 3 Units/mmole creatinine (means - 2 sigma) may be regarded as indication for instituting disintoxication therapy.

Adult↗
PubMed1988

[The results of the use of bleomycin and its analogs in the VAB-6 protocol in treating testicular tumors].

Efficacy and toxicity of VAB-6 combinations with bleomycin, bleomycetin or peplomycin were studied in treatment of 77 patients with metastases of germ-cell tumors: testicle tumors in 71 patients and extragonadal tumors in 6 patients. After the chemotherapy complete regression was observed in 37 patients (48.7 per cent). In 44 patients (57.1 per cent) residual metastases after the chemotherapy were resected. The frequency of complete regression after using the VAB-6 combinations with bleomycin, bleomycetin and peplomycin amounted to 58.8, 61.5 and 47.1 per cent respectively. The treatment results depended on the disease extent. When the disease extent was minimal complete regression was observed in 87.5 per cent of the patients. The respective figures for the disease moderate and significant extents were 66.7 and 37.8 per cent. During the average observation period of 22.1 months (7-40 months) 39 patients survived and had no signs of the disease. The combinations markedly differed in their toxicity.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

[Biological effects of leakadin].

57 patients with disseminated tumors of various sites received 10 daily doses of 600 mg/m2 leakadin intravenously. The immunostimulating effect was observed (OKT4/OKT8 normalization). The data on leakadin pharmacokinetics are discussed.

Adjuvants, Immunologic↗
PubMed1988

[Enhanced antitumor action of 5-fluorouracil when used in combination with 4-methylmercaptopyrazolo[3,4-d]pyrimidine 1-nucleoside].

Mice BDF1 with L 1210 or mice BALB/c with plasmacytoma MOPS-406 after pretreatment with ineffective doses of 1-beta-D-ribofuranosyl-4-methylmercaptopyrazolo(3,4-d)pyramidin e (25 to 100 mg/kg per 5 days) were treated with 5-fluorouracil at the optimal dose 100 mg per day. This combination produced a 1.5-2-fold or 2 to 4 fold enhancement of the antitumour effect of 5-fluorouracil without simultaneous increase of lethal toxicity.

Animals↗
PubMed1987

[Comparative evaluation of the effectiveness of radiotherapy and chemo-radiotherapy of stage III-IV nasopharyngeal cancer].

The paper is concerned with the results of radiation and chemoradiotherapy of stage III-IV rhinopharyngeal cancer. Short- and long-term therapeutic results, the time of a recurrence-free course, the frequency of recurrences and metastasizing, expression of reactions, and complications were used as criteria. The most effective method of combined therapy of locally spread rhinopharyngeal cancer was polychemotherapy (bleomycetin, methotrexate, vinblastine, and cyclophosphamide) before irradiation with subsequent maintenance cyclophosphamide chemotherapy once in 4 weeks for 3-6 months. The 5-year survival rate for combined modality therapy of stage III-IV rhinopharyngeal cancer was within 62%, for radiotherapy used alone-50%.

Adolescent↗
PubMed1987

[The use of aminoglutethimide (orimeten) in disseminated breast cancer].

Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%. Patients who had failed on tamoxifen responded to orimeten. Such side-effects as skin rash, drowsiness and cardiovascular disturbances were not pronounced. Limiting toxicity was 6%.

Adult↗
PubMed1987

[Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].

The report deals with the results of chemotherapy of 25 cases of advanced breast cancer. The patients had received tamoxifen + diethylstilbestrol (or chlorotrianizen) to stimulate a short-term proliferation in tumor and to potentiate the effect of cytostatic drugs. Complete regression of tumor was observed in I case and partial regression--in 12 cases (overall response--52%). Tumor growth stimulation effect was assessed on the basis of changes in DNA synthesis rate and proliferative pool as evidenced by repeated biopsy of tumor.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

[Management and drug therapy of patients with disseminated testicular tumors].

The experience gained in the treatment of 111 cases of testicular tumor is summarized in the paper. Methods of management of testicular cancer in the eighties differ significantly from those employed in the seventies. A set of drugs used is different. The share of cases of monochemotherapy has decreased markedly. PVB and VAB-6 schemes are highly effective inducing complete or partial remission in 80-90% of cases. Issues of treatment of patients with massive metastases in retroperitoneal lymph nodes and lungs remain unresolved. Timely diagnosis of dissemination will improve chemotherapy results.

Adult↗
PubMed1985

[Combination of platidiam and bleomycetin in disseminated skin melanoma].

Clinical trials of bleomycetin and platidiam combination were carried out in 13 patients with disseminated melanoma of the skin. Two regimens of the treatment were used. Regimen I included intravenous administration of platidiam in a dose of 20 mg/m2 with a water load on days 2, 3, 4, 5 and 6 of the treatment course and intravenous administration of bleomycetin in a dose of 30 mg/m2 on days 1 and 7. The intervals between the courses consisted of 4 weeks. Regimen II included the use of platidiam in a dose of 20 mg/m2 administered as 6-hour intravenous infusions in 1.2 1 of isotonic sodium chloride solution daily for 5 days. On the first day of this cycle bleomycetin was administered intravenously in a dose of 30 mg/m2. The cycles were performed during the 1st and the 3rd weeks of the treatment course. During the 2nd and the 4th weeks platidiam was administered in a dose of 40 mg/m2 once a week and bleomycetin was administered intramuscularly in a dose of 6 mg/m2 daily for 5 days. A more than 50 per cent decrease in the tumor formation was observed in 38 per cent of the patients. The combination had no toxic effect on hemopoiesis and may be used in new programs on chemotherapy of disseminated melanoma of the skin.

Adult↗
PubMed1985

[Ribamidyl (ribavirin) as a modulator of the biological action of arabinosylcytosine and methotrexate].

Administration of ribamidyl (Rb) prior to Ara-C to intact mice or mice with implanted tumours enhanced Ara-C toxicity. The growth of tumours (plasmacytoma MOPC-21, adenocarcinoma of the small intestine (strain AKATON), mammary adenocarcinoma 755 (Ca 755) resistant to Ara-C or Rb was inhibited after coadministration of these drugs. The augmentation of toxic and antitumour effects of Ara-C by Rb is similar to the described effect of high doses of thymidine. This is in accordance with the enhancement of the intracellular pool of thymidine phosphates under the action of Rb. The toxicity of methotrexate in vivo was increased by coadministration with Rb. This effect may be connected with a decrease in purine precursors pool under the action of Rb.

Animals↗